Verona Pharma price target raised to $77 from $51 at BTIG

Jan 8, 2025 · BTIG raised the firm’s price target on Verona Pharma (VRNA) to $77 from $51 and keeps a Buy rating on the shares. The company’s Q4 pre-announcement was "impressive", …

$77
OFF

Verona Pharma Price Target Raised To $77 From $51 At BTIG

2 weeks from now

Jan 8, 2025 · BTIG raised the firm’s price target on Verona Pharma (VRNA) to $77 from $51 and keeps a Buy rating on the shares. The company’s Q4 pre-announcement was "impressive", …

nasdaq.com

$77
OFF

Verona Pharma (VRNA) PT Raised To $77 At BTIG - Streetinsider.com

2 weeks from now

Jan 7, 2025 · BTIG analyst Thomas Shrader raised the price target on Verona Pharma (NASDAQ: VRNA) to $77.00 (from $51.00) while maintaining a Buy rating.The analyst comments "The …

streetinsider.com

$77
OFF

Verona Pharma Stock Target Raised To $77 At BTIG

2 weeks from now

Jan 7, 2025 · In other recent news, Verona Pharma (NASDAQ: VRNA) has reported positive financial developments, including preliminary fourth-quarter sales that exceeded expectations …

investing.com

$77
OFF

Verona Pharma Stock Target Raised To $77 At BTIG - Investing.com

2 weeks from now

Jan 7, 2025 · Verona Pharma stock target raised to $77 at BTIG. Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing …

investing.com

$77
OFF

Verona Pharma’s Growth Prospects Bolstered By ... - Markets Insider

2 weeks from now

Sep 11, 2024 · Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. ... Verona Pharma price target raised to $77 from $51 …

businessinsider.com

$31.00
OFF

BTIG Sticks To Their Buy Rating For Verona Pharma (VRNA)

2 weeks from now

Jun 28, 2023 · BTIG analyst Thomas Shrader maintained a Buy rating on Verona Pharma (VRNA – Research Report) yesterday and set a price target of $31.00. ...

businessinsider.com

$74
OFF

Verona Pharma Price Target Raised To $74 From $64 At Wells Fargo

2 weeks from now

Jan 8, 2025 · Wells Fargo analyst Tiago Fauth raised the firm’s price target on Verona Pharma (VRNA) to $74 from $64 and keeps an Overweight rating on the shares. The firm notes …

businessinsider.com

$74
OFF

Verona Pharma (VRNA) PT Raised To $74 At Wells Fargo

2 weeks from now

Jan 8, 2025 · Wells Fargo analyst Tiago Fauth raised the price target on Verona Pharma (NASDAQ: VRNA) to $74.00 (from $64.00) while maintaining a Overweight rating.

streetinsider.com

76%
OFF

Why Is Verona Pharma (VRNA) Stock Up 76% Today?

2 weeks from now

Aug 9, 2022 · Verona Pharma says that, if the ENHANCE-1 results are positive, it intends to move forward with a New Drug Application (NDA). This would likely happen in the first half of 2023. …

investorplace.com

$34
OFF

Verona Pharma (VRNA) PT Raised To $34 At BTIG - Streetinsider.com

2 weeks from now

Apr 23, 2024 · BTIG analyst Thomas Shrader raised the price target on Verona Pharma (NASDAQ: VRNA) to $34.00 (from $31.00) while maintaining a Buy rating.The analyst …

streetinsider.com

80%
OFF

Verona Pharma (VRNA) Insider Trading Activity 2025 - MarketBeat

2 weeks from now

Jan 8, 2025 · What percentage of Verona Pharma stock is owned by insiders? 4.80% of Verona Pharma stock is owned by insiders. Learn more on VRNA's insider holdings. Which Verona …

marketbeat.com

$57
OFF

Verona Pharma Price Target Raised To $57 From $44 At Truist

2 weeks from now

Jan 8, 2025 · Truist raised the firm’s price target on Verona Pharma (VRNA) to $57 from $44 and keeps a Buy rating on the shares. The firm cites the company’s positive Q4 revenue pre …

businessinsider.com

FAQs about Verona Pharma price target raised to $77 from $51 at BTIG Coupon?

Should you buy Verona Pharma (vRNA – research report)?

Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the stock and has a $36.00 price target. ...

What is the price target for Verona Pharma (vRNA)?

The highest price target for VRNA is $74.00, while the lowest price target for VRNA is $33.00. The average price target represents a forecasted upside of 14.23% from the current price of $44.27. Enter your email address to receive the latest news and analysts' ratings for Verona Pharma and its competitors. ...

Was Verona Pharma revisited by a Wall Street analyst today?

Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju... ...

Is Verona Pharma (vRNA) stock rising?

Verona Pharma ( VRNA) stock is rising alongside second-quarter earnings. The company also just posted positive clinical trial results. Heavy trading is pushing shares of VRNA stock higher this morning. ...

Where is Verona Pharma headquartered?

The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom. Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. ...

When did Verona Pharma IPO?

Verona Pharma (VRNA) raised $61 million in an initial public offering (IPO) on Thursday, April 27th 2017. The company issued 4,500,000 shares at a price of $13.49 per share. Jefferies and Stifel served as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers. ...